Many lung cancer patients will be detected by genetic testing to carry an EGFR mutation, and these patients can often control their tumours with EGFR-targeted drugs. Although targeted drugs are effective and have fewer side effects than chemotherapy, resistance to them inevitably occurs, after which they no longer work.
Medical
-
-
Many women suffering from hyperthyroidism hope to become pregnant or have a second child, but hyperthyroidism is a chronic disease, which often cannot be cured for a long time. Many people mistakenly believe that hyperthyroidism and pregnancy are absolutely "incompatible" and "irreconcilable", which undoubtedly brings a lot of gloom to patients' family life.
-
Medical
Study Shows Drug Halves Recurrence Rate In Patients With Early-Stage EGFR-Mutated Lung Cancer!
A new clinical trial update shows that oxitinib (known as Teresa, or 9291) nearly doubled disease-free survival and halved post-operative recurrence rates in lung cancer patients carrying an early stage EGFR mutation!
-
Data from a study recently published by the Royal Marsden Cancer Centre showed promising data for the combination of Avutometinib + Defactinib in the treatment of ovarian cancer, resulting in significant tumour shrinkage in 28% of patients and disease control in 93% of patients.
-
Medical
Three-drug Combination For HPV-positive Cancers Results In Significant Tumour Shrinkage In 88% Of Patients!
A three-drug combination regimen significantly prolongs survival in patients with HPV-positive cancers, new data from a clinical trial shows. For patients who had not been treated with immune checkpoint inhibitors, it resulted in significant tumour shrinkage in 88% of patients, and even in patients who failed immune checkpoint inhibitor treatment, 63% had significant tumour shrinkage.
-
Medical
New Study: Nmn Supplementation Activates Longevity Proteins To Reduce Stem Cell Senescence And Restore Mitochondrial Function
The development of an effective anti-aging drug and functional food to slow down ASCs' aging is crucial
-
Medical
Approved! With Just One Oral Dose Per Day, This Type Of Breast Cancer Patient Gets a New Drug
The US FDA has approved Elacestrant, the first oral selective estrogen receptor degrader (SERD), for the treatment of patients with advanced or metastatic breast cancer who are estrogen receptor positive, HER2 negative and have an ESR1 mutation. Results of the trial showed that patients treated with Elacestrant had a 45% reduction in the risk of disease progression or death.
-
Although immortality is still only a myth in the mirror, living a long and healthy life is a goal that most people seem to be able to achieve.
-
Medical
Neoadjuvant Chemotherapy Reduces Colon Cancer Recurrence Rate By 28%, With Fewer Post-Operative Complications, Study Shows
Preoperative oxaliplatin-fluoropyrimidine chemotherapy given to colon cancer patients did not increase the risk of perioperative complications in colon cancer patients and did reduce postoperative recurrence rates, according to the results of the international phase 3/4 FOxTROT trial.
-
Can patients with bridge onychiasis and hypothyroidism have normal childbearing?